KalVista Pharma Q1 2025 GAAP EPS $(0.87) Beats $(0.91) Estimate, Cash Balance Of $174.3M
Portfolio Pulse from Benzinga Newsdesk
KalVista Pharmaceuticals reported a Q1 2025 GAAP EPS of $(0.87), beating the estimated $(0.91). The company also has a cash balance of $174.3 million.
September 05, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
KalVista Pharmaceuticals reported better-than-expected Q1 2025 earnings with a GAAP EPS of $(0.87) compared to the estimated $(0.91). The company maintains a strong cash position with $174.3 million.
KalVista's better-than-expected earnings per share (EPS) is a positive indicator for the company's financial health, likely boosting investor confidence. The strong cash balance further supports the company's stability and potential for future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100